Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARVELOUS: Certolizumab Pegol in active rheumatoid arthritis
NCT01235598Phase 3Completed
- Sponsor
- UCB
- Start
- Dec 2010
- Primary completion
- Sep 2012
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 4
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Dec 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01235598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01235598.